.png)
Molecular Diagnostics Cancer Market by Type and Application- Global Industry Analysis & Forecast to 2027
Published On : December 2020 Pages : 154 Category: Pharma & Healthcare Report Code : HC1214478
SEGMENTS & REGIONS:
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Molecular Diagnostics Cancer Market By Type (Pharmacogenomic Diagnosis, Liquid Biopsy, Other) and Application (Respiratory Cancer, Cancer of Digestive System, Cancer of Urinary System, Cancer of Circulatory System, Motor System Cancer, Reproductive System Cancer, Other)- Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Molecular Diagnostics Cancer Markethas encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period.A cancer molecular diagnosis is a laboratory test that examines certain genes, proteins, or other molecules in a sample of tissue, blood, or other body fluids. It also examines certain changes in genes or chromosomes that may cause or affect the chances of developing cancer. It can also be used to help plan treatment and find out treatment effects or prognosis.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global Molecular Diagnostics Cancer Market size market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- SouthAmerica
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Roche
- Danaher
- Siemens
- Abbott Laboratories
- ICON Plc
- AstraZeneca
- MDxHealth
- Invitae
- PlexBio
- Thermo Fisher Scientific
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2021 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Molecular Diagnostics Cancer Market, ByType, Estimates and Forecast, 2017-2027 ($Million)
o Pharmacogenomic Diagnosis
o Liquid Biopsy
o Other
· Molecular Diagnostics Cancer Market, ByApplication, Estimates and Forecast, 2017-2027 ($Million)
o Respiratory Cancer
o Cancer of Digestive System
o Cancer of Urinary System
o Cancer of Circulatory System
o Motor System Cancer
o Reproductive System Cancer
o Other
· Molecular Diagnostics Cancer Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Roche
o Danaher
o Siemens
o Abbott Laboratories
o ICON Plc
o AstraZeneca
o Invitae
o PlexBio
o Thermo Fisher Scientific
· Molecular Diagnostics Cancer Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Molecular Diagnostics Cancer Market, By Country
o U.S. Molecular Diagnostics Cancer Market
o Canada Molecular Diagnostics Cancer Market
o Mexico Molecular Diagnostics Cancer Market
o Europe
§ Europe Molecular Diagnostics Cancer Market, By Country
· Germany Molecular Diagnostics Cancer Market
o UK Molecular Diagnostics Cancer Market
o France Molecular Diagnostics Cancer Market
o RussiaMolecular Diagnostics Cancer Market
o Italy Molecular Diagnostics Cancer Market
o Rest of Europe Molecular Diagnostics Cancer Market
o Asia-Pacific
§ Asia-Pacific Molecular Diagnostics Cancer Market, By Country
o ChinaMolecular Diagnostics Cancer Market
o Japan Molecular Diagnostics Cancer Market
o South KoreaMolecular Diagnostics Cancer Market
o India Molecular Diagnostics Cancer Market
o Southeast AsiaMolecular Diagnostics Cancer Market
o Rest of Asia-Pacific Molecular Diagnostics Cancer Market
o South America
§ South AmericaMolecular Diagnostics Cancer Market
o Brazil Molecular Diagnostics Cancer Market
o ArgentinaMolecular Diagnostics Cancer Market
o ColumbiaMolecular Diagnostics Cancer Market
o Rest of South America Molecular Diagnostics Cancer Market
o Middle East and Africa
§ Middle East and AfricaMolecular Diagnostics Cancer Market
o Saudi ArabiaMolecular Diagnostics Cancer Market
o UAEMolecular Diagnostics Cancer Market
o EgyptMolecular Diagnostics Cancer Market
o NigeriaMolecular Diagnostics Cancer Market
o South Africa Molecular Diagnostics Cancer Market
o Rest of MEA Molecular Diagnostics Cancer Market
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Molecular Diagnostics Cancer Market, By Type
5.1. Introduction
5.2. Global Molecular Diagnostics Cancer Revenue and Market Share by Type (2017-2021)
5.2.1. Global Molecular Diagnostics Cancer Revenue and Revenue Share by Type (2017-2021)
5.3. Pharmacogenomic Diagnosis
5.3.1. Global Pharmacogenomic Diagnosis Revenue and Growth Rate (2017-2021)
5.4. Liquid Biopsy
5.4.1. Global Liquid Biopsy Revenue and Growth Rate (2017-2021)
5.5. Other
5.5.1. Global Other Revenue and Growth Rate (2017-2021)
6. Molecular Diagnostics Cancer Market, By Application
6.1. Introduction
6.2. Global Molecular Diagnostics Cancer Revenue and Market Share by Application (2017-2021)
6.2.1. Global Molecular Diagnostics Cancer Revenue and Revenue Share by Application (2017-2021)
6.3. Respiratory Cancer
6.3.1. Global Respiratory Cancer Revenue and Growth Rate (2017-2021)
6.4. Cancer of Digestive System
6.4.1. Global Cancer of Digestive System Revenue and Growth Rate (2017-2021)
6.5. Cancer of Urinary System
6.5.1. Global Cancer of Urinary System Revenue and Growth Rate (2017-2021)
6.6. Cancer of Circulatory System
6.6.1. Global Cancer of Circulatory System Revenue and Growth Rate (2017-2021)
6.7. Motor System Cancer
6.7.1. Global Motor System Cancer Revenue and Growth Rate (2017-2021)
6.8. Reproductive System Cancer
6.8.1. Global Reproductive System Cancer Revenue and Growth Rate (2017-2021)
6.9. Other
6.9.1. Global Other Revenue and Growth Rate (2017-2021)
7. Molecular Diagnostics Cancer Market, By Region
7.1. Introduction
7.2. Global Molecular Diagnostics Cancer Revenue and Market Share by Regions
7.2.1. Global Molecular Diagnostics Cancer Revenue by Regions (2017-2021)
7.3. North America Molecular Diagnostics Cancer by Countries
7.3.1. North America Molecular Diagnostics Cancer Revenue and Growth Rate (2017-2021)
7.3.2. North America Molecular Diagnostics Cancer Revenue (Million USD) by Countries (2017-2021)
7.3.3. United States
7.3.3.1. United States Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.4. Canada
7.3.4.1. Canada Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.5. Mexico
7.3.5.1. Mexico Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.4. Europe Molecular Diagnostics Cancer by Countries
7.4.1. Europe Molecular Diagnostics Cancer Revenue and Growth Rate (2017-2021)
7.4.2. Europe Molecular Diagnostics Cancer Revenue (Million USD) by Countries (2017-2021)
7.4.3. Germany
7.4.3.1. Germany Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.4. France
7.4.4.1. France Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.5. UK
7.4.5.1. UK Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.6. Russia
7.4.6.1. Russia Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.7. Italy
7.4.7.1. Italy Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.5. Asia-Pacific Molecular Diagnostics Cancer by Countries
7.5.1. Asia-Pacific Molecular Diagnostics Cancer Revenue and Growth Rate (2017-2021)
7.5.2. Asia-Pacific Molecular Diagnostics Cancer Revenue (Million USD) by Countries (2017-2021)
7.5.3. China
7.5.3.1. China Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.4. Japan
7.5.4.1. Japan Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.5. Korea
7.5.5.1. Korea Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.6. India
7.5.6.1. India Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.6. South America Molecular Diagnostics Cancer by Countries
7.6.1. South America Molecular Diagnostics Cancer Revenue and Growth Rate (2017-2021)
7.6.2. South America Molecular Diagnostics Cancer Revenue (Million USD) by Countries (2017-2021)
7.6.3. Brazil
7.6.3.1. Brazil Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.4. Argentina
7.6.4.1. Argentina Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.5. Columbia
7.6.5.1. Columbia Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.7. Middle East and Africa Molecular Diagnostics Cancer by Countries
7.7.1. Middle East and Africa Molecular Diagnostics Cancer Revenue and Growth Rate (2017-2021)
7.7.2. Middle East and Africa Molecular Diagnostics Cancer Revenue (Million USD) by Countries (2017-2021)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.5. Egypt
7.7.5.1. Egypt Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.6. Nigeria
7.7.6.1. Nigeria Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.7. South Africa
7.7.7.1. South Africa Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.8. Turkey
7.7.8.1. Turkey Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2021)
8. Company Profiles
8.1. Roche
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Danaher
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Siemens
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Abbott Laboratories
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. ICON Plc
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. AstraZeneca
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. MDxHealth
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. Invitae
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
8.9. PlexBio
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Financial Overview
8.10. Thermo Fisher ScientificxHealth
8.10.1. Business Overview
8.10.2. Service Portfolio
8.10.3. Strategic Developments
8.10.4. Financial Overview
8.11. Invitae
8.11.1. Business Overview
8.11.2. Service Portfolio
8.11.3. Strategic Developments
8.11.4. Financial Overview
8.12. PlexBio
8.12.1. Business Overview
8.12.2. Service Portfolio
8.12.3. Strategic Developments
8.12.4. Financial Overview
8.13. Thermo Fisher Scientific
8.13.1. Business Overview
8.13.2. Service Portfolio
8.13.3. Strategic Developments
8.13.4. Financial Overview
9. Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.1. Global Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2022-2027)
9.2. Molecular Diagnostics Cancer Market Forecast by Regions (2022-2027)
9.2.1. North America Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.1.1. United States Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.1.2. Canada Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.1.3. Mexico Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.2. Europe Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.2.1. Germany Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.2.2. France Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.2.3. UK Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.2.4. Russia Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.2.5. Italy Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.2.6. Rest of Europe Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.3. Asia-Pacific Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.3.1. China Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.3.2. Japan Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.3.3. Korea Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.3.4. India Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.3.5. Southeast Asia Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.3.6. Rest of Asia-Pacific Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.4. South America Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.4.1. Brazil Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.4.2. Argentina Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.4.3. Columbia Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.4.4. Rest of South America Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.5. Middle East and Africa Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.5.1. Saudi Arabia Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.5.2. United Arab Emirates Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.5.3. Egypt Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.5.4. Nigeria Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.5.5. South Africa Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.5.6. Turkey Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.2.5.7. Rest of Middle East and Africa Molecular Diagnostics Cancer Market Forecast (2022-2027)
9.3. Molecular Diagnostics Cancer Market Forecast by Type (2022-2027)
9.3.1. Molecular Diagnostics Cancer Forecast by Type (2022-2027)
9.3.2. Molecular Diagnostics Cancer Market Share Forecast by Type (2022-2027)
9.4. Molecular Diagnostics Cancer Market Forecast by Application (2022-2027)
9.4.1. Molecular Diagnostics Cancer Forecast by Application (2022-2027)
9.4.2. Molecular Diagnostics Cancer Market Share Forecast by Application (2022-2027)
List of Tables
List of Tables and Figures:
Figure United States Molecular Diagnostics Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Molecular Diagnostics Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Molecular Diagnostics Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Molecular Diagnostics Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Molecular Diagnostics Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Molecular Diagnostics Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Molecular Diagnostics Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Molecular Diagnostics Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Molecular Diagnostics Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Molecular Diagnostics Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Molecular Diagnostics Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Molecular Diagnostics Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Molecular Diagnostics Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Molecular Diagnostics Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Molecular Diagnostics Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Molecular Diagnostics Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Molecular Diagnostics Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Molecular Diagnostics Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Molecular Diagnostics Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Molecular Diagnostics Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Molecular Diagnostics Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Molecular Diagnostics Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Molecular Diagnostics Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Molecular Diagnostics Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Molecular Diagnostics Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Molecular Diagnostics Cancer Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Molecular Diagnostics Cancer Revenue and Revenue Share by Type (2017-2019)
Figure Global Pharmacogenomic Diagnosis Revenue and Growth Rate (2017-2019)
Figure Global Liquid Biopsy Revenue and Growth Rate (2017-2019)
Figure Global Other Revenue and Growth Rate (2017-2019)
Table Global Molecular Diagnostics Cancer Revenue and Revenue Share by Application (2017-2019)
Figure Global Respiratory Cancer Revenue and Growth Rate (2017-2019)
Figure Global Cancer of Digestive System Revenue and Growth Rate (2017-2019)
Figure Global Cancer of Urinary System Revenue and Growth Rate (2017-2019)
Figure Global Cancer of Circulatory System Revenue and Growth Rate (2017-2019)
Figure Global Motor System Cancer Revenue and Growth Rate (2017-2019)
Figure Global Reproductive System Cancer Revenue and Growth Rate (2017-2019)
Figure Global Other Revenue and Growth Rate (2017-2019)
Table Global Molecular Diagnostics Cancer Revenue by Regions (2017-2019)
Figure North America Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure North America Molecular Diagnostics Cancer Revenue and Growth Rate (2017-2019)
Figure North America Molecular Diagnostics Cancer by Countries (2017-2019)
Figure North America Molecular Diagnostics Cancer Revenue (Million USD) by Countries (2017-2019)
Figure United States Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure United States Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Canada Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure Canada Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Mexico Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure Mexico Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Europe Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure Europe Molecular Diagnostics Cancer Revenue and Growth Rate (2017-2019)
Figure Europe Molecular Diagnostics Cancer by Countries (2017-2019)
Figure Europe Molecular Diagnostics Cancer Revenue (Million USD) by Countries (2017-2019)
Figure Germany Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure Germany Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure France Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure France Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure UK Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure UK Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Russia Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure Russia Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Italy Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure Italy Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Europe Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure Rest of Europe Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Asia-Pacific Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure Asia-Pacific Molecular Diagnostics Cancer Revenue and Growth Rate (2017-2019)
Figure Asia-Pacific Molecular Diagnostics Cancer by Countries (2017-2019)
Figure Asia-Pacific Molecular Diagnostics Cancer Revenue (Million USD) by Countries (2017-2019)
Figure China Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure China Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Japan Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure Japan Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Korea Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure Korea Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure India Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure India Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Southeast Asia Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure Southeast Asia Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South America Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure South America Molecular Diagnostics Cancer Revenue and Growth Rate (2017-2019)
Figure South America Molecular Diagnostics Cancer by Countries (2017-2019)
Figure South America Molecular Diagnostics Cancer Revenue (Million USD) by Countries (2017-2019)
Figure Brazil Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure Brazil Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Argentina Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure Argentina Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Columbia Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure Columbia Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of South America Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure Rest of South America Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Middle East and Africa Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure Middle East and Africa Molecular Diagnostics Cancer Revenue and Growth Rate (2017-2019)
Figure Middle East and Africa Molecular Diagnostics Cancer by Countries (2017-2019)
Figure Middle East and Africa Molecular Diagnostics Cancer Revenue (Million USD) by Countries (2017-2019)
Figure Saudi Arabia Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure Saudi Arabia Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure United Arab Emirates Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure United Arab Emirates Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Egypt Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure Egypt Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Nigeria Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure Nigeria Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South Africa Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure South Africa Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Turkey Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure Turkey Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Molecular Diagnostics Cancer Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2017-2019)
Table Roche Molecular Diagnostics Cancer Financial Overview
Table Danaher Molecular Diagnostics Cancer Financial Overview
Table Siemens Molecular Diagnostics Cancer Financial Overview
Table Abbott Laboratories Molecular Diagnostics Cancer Financial Overview
Table ICON Plc Molecular Diagnostics Cancer Financial Overview
Table AstraZeneca Molecular Diagnostics Cancer Financial Overview
Table MDxHealth Molecular Diagnostics Cancer Financial Overview
Table Invitae Molecular Diagnostics Cancer Financial Overview
Table PlexBio Molecular Diagnostics Cancer Financial Overview
Table Thermo Fisher ScientificxHealth Molecular Diagnostics Cancer Financial Overview
Table Invitae Molecular Diagnostics Cancer Financial Overview
Table PlexBio Molecular Diagnostics Cancer Financial Overview
Table Thermo Fisher Scientific Molecular Diagnostics Cancer Financial Overview
Figure Global Molecular Diagnostics Cancer Revenue (Millions USD) and Growth Rate (2019-2027)
Table Molecular Diagnostics Cancer Market Forecast by Regions (2019-2027)
Figure North America Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure United States Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure Canada Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure Mexico Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure Europe Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure Germany Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure France Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure UK Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure Russia Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure Italy Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure Rest of Europe Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure Asia-Pacific Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure China Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure Japan Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure Korea Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure India Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure Southeast Asia Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure Rest of Asia-Pacific Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure South America Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure Brazil Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure Argentina Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure Columbia Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure Rest of South America Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure Middle East and Africa Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure Saudi Arabia Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure United Arab Emirates Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure Egypt Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure Nigeria Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure South Africa Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure Turkey Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure Rest of Middle East and Africa Molecular Diagnostics Cancer Market Forecast (2019-2027)
Figure Global Molecular Diagnostics Cancer Forecast by Type (2019-2027)
Figure Global Molecular Diagnostics Cancer Market Share Forecast by Type (2019-2027)
Figure Global Molecular Diagnostics Cancer Forecast by Type (2019-2027)
Figure Global Molecular Diagnostics Cancer Forecast by Application (2019-2027)
Figure Global Molecular Diagnostics Cancer Market Share Forecast by Application (2019-2027)
Figure Global Molecular Diagnostics Cancer Forecast by Application (2019-2027)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|